Deal Lawyers

article thumbnail

7th Cir. Fires Another Shot at Mootness Fee Awards

Deal Lawyers

The 7th Circuit was one of the first federal courts to take a dubious view of mootness fee awards in M&A disclosure litigation, and its decision last month in Alcarez v. Akorn, (7th. Cir; 4/24), suggests that the Court’s views haven’t mellowed with time.

M&A 122
article thumbnail

Private Equity: It Didn’t Start When We Think It Did

Deal Lawyers

If you’ve been reading this blog for a while, you know I’ve got a soft spot for M&A history. That’s why this CLS Blue Sky Blog discussing a new article on the history of private equity caught my eye.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

“Deja Vu All Over Again”: Delaware Supreme Court Overrules Chancery on Disclosure of Advisor Conflicts

Deal Lawyers

The Delaware Supreme Court doesn’t appear to be seeing eye-to-eye with the Chancery Court when it comes to disclosure of advisor conflicts.

IT 112
article thumbnail

Study: Private Target Deal Terms

Deal Lawyers

SRS Acquiom recently released its annual M&A Deal Terms Study for 2024 (available for download). This year, SRS Acquiom analyzed more than 2,100 private-target acquisitions that closed from 2018 through 2023. Here are some of the key findings summarized in the introduction: – Strategic buyers (both U.S.

M&A 100
article thumbnail

ESG Due Diligence: Now Mandatory?

Deal Lawyers

This survey by BCG and Gibson Dunn concludes that ESG due diligence has become “indispensable” for M&A. Two-thirds of survey respondents have engaged on ESG topics during transactions, and 75% reported that they identified a material ESG issue in a deal in the last three years because they conducted due diligence.

M&A 122
article thumbnail

DE Chancery: “Commercially Reasonable” Doesn’t Require Actions Beyond Buyer’s Self-Interest

Deal Lawyers

Himawan v. Cephalon, Inc. (Del. Ch.; 4/24) presents a familiar fact pattern in life-sciences M&A. The target biotech company was developing one main asset for two possible indications. In its acquisition by Cephalon, its stockholders were entitled to “milestone” payments tied to regulatory approval of the asset for those indications.

M&A 122
article thumbnail

M&A Trends: 2024 Edition of Wachtell’s “Takeover Law & Practice”

Deal Lawyers

Wachtell Lipton recently published the 2024 edition of its 237-page “Takeover Law and Practice” publication.

M&A 112